Synthesis of Sch 51048, a novel orally active azole antifungal, is des
cribed. Based on its superior oral efficacy over other available agent
s against a variety of fungal pathogens in normal and immunocompromise
d animal infection models, Sch 51048 is a subject for possible clinica
l evaluation.